John F Reilly Jr, DO - Medicare Emergency Medicine in Broomall, PA

John F Reilly Jr, DO is a medicare enrolled "Emergency Medicine" physician in Broomall, Pennsylvania. He went to Philadelphia College Of Osteopathic Medicine and graduated in 1982 and has 42 years of diverse experience with area of expertise as Emergency Medicine. He is a member of the group practice Main Line Healthcare, Radnor Family Practice Professional Limited Liability Company and his current practice location is 1991 Sproul Rd, Suite 600, Broomall, Pennsylvania. You can reach out to his office (for appointments etc.) via phone at (484) 421-1669.

John F Reilly Jr is licensed to practice in Pennsylvania (license number OS005078L) and he also participates in the medicare program. He accepts medicare assignments (which means he accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance) and his NPI Number is 1407825854.

Contact Information

John F Reilly Jr, DO
1991 Sproul Rd, Suite 600,
Broomall, PA 19008-3512
(484) 421-1669
(610) 886-0164



Physician's Profile

Full NameJohn F Reilly Jr
GenderMale
SpecialityEmergency Medicine
Experience42 Years
Location1991 Sproul Rd, Broomall, Pennsylvania
Accepts Medicare AssignmentsYes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance.
  Medical Education and Training:
  • John F Reilly Jr attended and graduated from Philadelphia College Of Osteopathic Medicine in 1982
  NPI Data:
  • NPI Number: 1407825854
  • Provider Enumeration Date: 03/17/2006
  • Last Update Date: 08/15/2016
  Medicare PECOS Information:
  • PECOS PAC ID: 2961450648
  • Enrollment ID: I20050110000532

Medical Identifiers

Medical identifiers for John F Reilly Jr such as npi, medicare ID, medicare PIN, medicaid, etc.
IdentifierTypeStateIssuer
1407825854NPI-NPPES

Medical Taxonomies and Licenses

TaxonomyTypeLicense (State)Status
207P00000XEmergency Medicine OS005078L (Pennsylvania)Primary

Medical Facilities Affiliation

Facility NameLocationFacility Type
Main Line Hospital LankenauWynnewood, PAHospital

Group Practice Association

Group Practice NameGroup PECOS PAC IDNo. of Members
Main Line Healthcare1951215201894
Radnor Family Practice Professional Limited Liability Company418367636414

News Archive

Politics continue to play out around Planned Parenthood funding

As 41 senators vow to filibuster any spending bill that includes an amendment to delete this funding, an anti-abortion group touts the opposite position taken by possible GOP 2012 presidential candidates.

JACC: Heart Failure from American College of Cardiology and Elsevier

Elsevier, a world-leading provider of scientific, technical and medical information products and services, and the American College of Cardiology (ACC) are pleased to announce that the American College of Cardiology (ACC) journals' portfolio has been expanded with the launch of JACC: Heart Failure.

Defects in original version of Neuron 6F 070 delivery catheter: Penumbra initiates voluntary field removal

Penumbra is initiating a voluntary Field Removal of the original version of Neuron 6F 070 Delivery Catheter. For these catheters, Penumbra has received feedback from some users that the catheter could kink or ovalize in certain anatomical situations.

Columbia University launches CovidWatcher app to track virus spread in NYC

Researchers from Columbia University have launched CovidWatcher, an app that surveys users about their exposure to the new coronavirus, symptoms, access to medical care, and impact on daily life.

CytRx's bafetinib demonstrates significant inhibition of glioblastoma multiforme cell lines in preclinical trial

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced that its drug candidate bafetinib (formerly known as INNO-406) demonstrated statistically significant inhibition of glioblastoma multiforme cell lines in a preclinical trial. Glioblastoma multiforme is the most common and aggressive primary adult brain tumor.

Read more Medical News

› Verified 7 days ago

Medicare Reassignments

Some practitioners may not bill the customers directly but medicare billing happens through clinics / group practice / hospitals where the provider works. Medicare reassignment of benefits is a mechanism by which practitioners allow third parties to bill and receive payment for medicare services performed by them. John F Reilly Jr allows following entities to bill medicare on his behalf.
Entity NamePinnacle Health Emergency Department Services, Llc
Entity TypePart B Supplier - Clinic/group Practice
Entity IdentifiersNPI Number: 1487693404
PECOS PAC ID: 0143124701
Enrollment ID: O20031125000218

News Archive

Politics continue to play out around Planned Parenthood funding

As 41 senators vow to filibuster any spending bill that includes an amendment to delete this funding, an anti-abortion group touts the opposite position taken by possible GOP 2012 presidential candidates.

JACC: Heart Failure from American College of Cardiology and Elsevier

Elsevier, a world-leading provider of scientific, technical and medical information products and services, and the American College of Cardiology (ACC) are pleased to announce that the American College of Cardiology (ACC) journals' portfolio has been expanded with the launch of JACC: Heart Failure.

Defects in original version of Neuron 6F 070 delivery catheter: Penumbra initiates voluntary field removal

Penumbra is initiating a voluntary Field Removal of the original version of Neuron 6F 070 Delivery Catheter. For these catheters, Penumbra has received feedback from some users that the catheter could kink or ovalize in certain anatomical situations.

Columbia University launches CovidWatcher app to track virus spread in NYC

Researchers from Columbia University have launched CovidWatcher, an app that surveys users about their exposure to the new coronavirus, symptoms, access to medical care, and impact on daily life.

CytRx's bafetinib demonstrates significant inhibition of glioblastoma multiforme cell lines in preclinical trial

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced that its drug candidate bafetinib (formerly known as INNO-406) demonstrated statistically significant inhibition of glioblastoma multiforme cell lines in a preclinical trial. Glioblastoma multiforme is the most common and aggressive primary adult brain tumor.

Read more Medical News

› Verified 7 days ago

Entity NameYork Hospital
Entity TypePart B Supplier - Clinic/group Practice
Entity IdentifiersNPI Number: 1326060492
PECOS PAC ID: 2961307467
Enrollment ID: O20031205000629

News Archive

Politics continue to play out around Planned Parenthood funding

As 41 senators vow to filibuster any spending bill that includes an amendment to delete this funding, an anti-abortion group touts the opposite position taken by possible GOP 2012 presidential candidates.

JACC: Heart Failure from American College of Cardiology and Elsevier

Elsevier, a world-leading provider of scientific, technical and medical information products and services, and the American College of Cardiology (ACC) are pleased to announce that the American College of Cardiology (ACC) journals' portfolio has been expanded with the launch of JACC: Heart Failure.

Defects in original version of Neuron 6F 070 delivery catheter: Penumbra initiates voluntary field removal

Penumbra is initiating a voluntary Field Removal of the original version of Neuron 6F 070 Delivery Catheter. For these catheters, Penumbra has received feedback from some users that the catheter could kink or ovalize in certain anatomical situations.

Columbia University launches CovidWatcher app to track virus spread in NYC

Researchers from Columbia University have launched CovidWatcher, an app that surveys users about their exposure to the new coronavirus, symptoms, access to medical care, and impact on daily life.

CytRx's bafetinib demonstrates significant inhibition of glioblastoma multiforme cell lines in preclinical trial

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced that its drug candidate bafetinib (formerly known as INNO-406) demonstrated statistically significant inhibition of glioblastoma multiforme cell lines in a preclinical trial. Glioblastoma multiforme is the most common and aggressive primary adult brain tumor.

Read more Medical News

› Verified 7 days ago

Entity NameMain Line Healthcare
Entity TypePart B Supplier - Clinic/group Practice
Entity IdentifiersNPI Number: 1922077643
PECOS PAC ID: 1951215201
Enrollment ID: O20040308000373

News Archive

Politics continue to play out around Planned Parenthood funding

As 41 senators vow to filibuster any spending bill that includes an amendment to delete this funding, an anti-abortion group touts the opposite position taken by possible GOP 2012 presidential candidates.

JACC: Heart Failure from American College of Cardiology and Elsevier

Elsevier, a world-leading provider of scientific, technical and medical information products and services, and the American College of Cardiology (ACC) are pleased to announce that the American College of Cardiology (ACC) journals' portfolio has been expanded with the launch of JACC: Heart Failure.

Defects in original version of Neuron 6F 070 delivery catheter: Penumbra initiates voluntary field removal

Penumbra is initiating a voluntary Field Removal of the original version of Neuron 6F 070 Delivery Catheter. For these catheters, Penumbra has received feedback from some users that the catheter could kink or ovalize in certain anatomical situations.

Columbia University launches CovidWatcher app to track virus spread in NYC

Researchers from Columbia University have launched CovidWatcher, an app that surveys users about their exposure to the new coronavirus, symptoms, access to medical care, and impact on daily life.

CytRx's bafetinib demonstrates significant inhibition of glioblastoma multiforme cell lines in preclinical trial

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced that its drug candidate bafetinib (formerly known as INNO-406) demonstrated statistically significant inhibition of glioblastoma multiforme cell lines in a preclinical trial. Glioblastoma multiforme is the most common and aggressive primary adult brain tumor.

Read more Medical News

› Verified 7 days ago

Entity NameTower Health Medical Group
Entity TypePart B Supplier - Clinic/group Practice
Entity IdentifiersNPI Number: 1609291350
PECOS PAC ID: 7618889213
Enrollment ID: O20040311000072

News Archive

Politics continue to play out around Planned Parenthood funding

As 41 senators vow to filibuster any spending bill that includes an amendment to delete this funding, an anti-abortion group touts the opposite position taken by possible GOP 2012 presidential candidates.

JACC: Heart Failure from American College of Cardiology and Elsevier

Elsevier, a world-leading provider of scientific, technical and medical information products and services, and the American College of Cardiology (ACC) are pleased to announce that the American College of Cardiology (ACC) journals' portfolio has been expanded with the launch of JACC: Heart Failure.

Defects in original version of Neuron 6F 070 delivery catheter: Penumbra initiates voluntary field removal

Penumbra is initiating a voluntary Field Removal of the original version of Neuron 6F 070 Delivery Catheter. For these catheters, Penumbra has received feedback from some users that the catheter could kink or ovalize in certain anatomical situations.

Columbia University launches CovidWatcher app to track virus spread in NYC

Researchers from Columbia University have launched CovidWatcher, an app that surveys users about their exposure to the new coronavirus, symptoms, access to medical care, and impact on daily life.

CytRx's bafetinib demonstrates significant inhibition of glioblastoma multiforme cell lines in preclinical trial

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced that its drug candidate bafetinib (formerly known as INNO-406) demonstrated statistically significant inhibition of glioblastoma multiforme cell lines in a preclinical trial. Glioblastoma multiforme is the most common and aggressive primary adult brain tumor.

Read more Medical News

› Verified 7 days ago

Entity NameRadnor Family Practice Professional Limited Liability Company
Entity TypePart B Supplier - Clinic/group Practice
Entity IdentifiersNPI Number: 1750407144
PECOS PAC ID: 4183676364
Enrollment ID: O20050216000158

News Archive

Politics continue to play out around Planned Parenthood funding

As 41 senators vow to filibuster any spending bill that includes an amendment to delete this funding, an anti-abortion group touts the opposite position taken by possible GOP 2012 presidential candidates.

JACC: Heart Failure from American College of Cardiology and Elsevier

Elsevier, a world-leading provider of scientific, technical and medical information products and services, and the American College of Cardiology (ACC) are pleased to announce that the American College of Cardiology (ACC) journals' portfolio has been expanded with the launch of JACC: Heart Failure.

Defects in original version of Neuron 6F 070 delivery catheter: Penumbra initiates voluntary field removal

Penumbra is initiating a voluntary Field Removal of the original version of Neuron 6F 070 Delivery Catheter. For these catheters, Penumbra has received feedback from some users that the catheter could kink or ovalize in certain anatomical situations.

Columbia University launches CovidWatcher app to track virus spread in NYC

Researchers from Columbia University have launched CovidWatcher, an app that surveys users about their exposure to the new coronavirus, symptoms, access to medical care, and impact on daily life.

CytRx's bafetinib demonstrates significant inhibition of glioblastoma multiforme cell lines in preclinical trial

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced that its drug candidate bafetinib (formerly known as INNO-406) demonstrated statistically significant inhibition of glioblastoma multiforme cell lines in a preclinical trial. Glioblastoma multiforme is the most common and aggressive primary adult brain tumor.

Read more Medical News

› Verified 7 days ago

Entity NamePennsylvania Urgent Care Centers, Pllc
Entity TypePart B Supplier - Clinic/group Practice
Entity IdentifiersNPI Number: 1902128721
PECOS PAC ID: 8123200631
Enrollment ID: O20110304000289

News Archive

Politics continue to play out around Planned Parenthood funding

As 41 senators vow to filibuster any spending bill that includes an amendment to delete this funding, an anti-abortion group touts the opposite position taken by possible GOP 2012 presidential candidates.

JACC: Heart Failure from American College of Cardiology and Elsevier

Elsevier, a world-leading provider of scientific, technical and medical information products and services, and the American College of Cardiology (ACC) are pleased to announce that the American College of Cardiology (ACC) journals' portfolio has been expanded with the launch of JACC: Heart Failure.

Defects in original version of Neuron 6F 070 delivery catheter: Penumbra initiates voluntary field removal

Penumbra is initiating a voluntary Field Removal of the original version of Neuron 6F 070 Delivery Catheter. For these catheters, Penumbra has received feedback from some users that the catheter could kink or ovalize in certain anatomical situations.

Columbia University launches CovidWatcher app to track virus spread in NYC

Researchers from Columbia University have launched CovidWatcher, an app that surveys users about their exposure to the new coronavirus, symptoms, access to medical care, and impact on daily life.

CytRx's bafetinib demonstrates significant inhibition of glioblastoma multiforme cell lines in preclinical trial

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced that its drug candidate bafetinib (formerly known as INNO-406) demonstrated statistically significant inhibition of glioblastoma multiforme cell lines in a preclinical trial. Glioblastoma multiforme is the most common and aggressive primary adult brain tumor.

Read more Medical News

› Verified 7 days ago

Entity NamePinnacle Health Observation Services Llc
Entity TypePart B Supplier - Clinic/group Practice
Entity IdentifiersNPI Number: 1316341241
PECOS PAC ID: 9537481528
Enrollment ID: O20141202001034

News Archive

Politics continue to play out around Planned Parenthood funding

As 41 senators vow to filibuster any spending bill that includes an amendment to delete this funding, an anti-abortion group touts the opposite position taken by possible GOP 2012 presidential candidates.

JACC: Heart Failure from American College of Cardiology and Elsevier

Elsevier, a world-leading provider of scientific, technical and medical information products and services, and the American College of Cardiology (ACC) are pleased to announce that the American College of Cardiology (ACC) journals' portfolio has been expanded with the launch of JACC: Heart Failure.

Defects in original version of Neuron 6F 070 delivery catheter: Penumbra initiates voluntary field removal

Penumbra is initiating a voluntary Field Removal of the original version of Neuron 6F 070 Delivery Catheter. For these catheters, Penumbra has received feedback from some users that the catheter could kink or ovalize in certain anatomical situations.

Columbia University launches CovidWatcher app to track virus spread in NYC

Researchers from Columbia University have launched CovidWatcher, an app that surveys users about their exposure to the new coronavirus, symptoms, access to medical care, and impact on daily life.

CytRx's bafetinib demonstrates significant inhibition of glioblastoma multiforme cell lines in preclinical trial

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced that its drug candidate bafetinib (formerly known as INNO-406) demonstrated statistically significant inhibition of glioblastoma multiforme cell lines in a preclinical trial. Glioblastoma multiforme is the most common and aggressive primary adult brain tumor.

Read more Medical News

› Verified 7 days ago

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. John F Reilly Jr is enrolled with medicare and thus, if eligible, can prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing AddressPractice Location Address
John F Reilly Jr, DO
1991 Sproul Rd, Suite 600,
Broomall, PA 19008-3512

Ph: (484) 421-1669
John F Reilly Jr, DO
1991 Sproul Rd, Suite 600,
Broomall, PA 19008-3512

Ph: (484) 421-1669

News Archive

Politics continue to play out around Planned Parenthood funding

As 41 senators vow to filibuster any spending bill that includes an amendment to delete this funding, an anti-abortion group touts the opposite position taken by possible GOP 2012 presidential candidates.

JACC: Heart Failure from American College of Cardiology and Elsevier

Elsevier, a world-leading provider of scientific, technical and medical information products and services, and the American College of Cardiology (ACC) are pleased to announce that the American College of Cardiology (ACC) journals' portfolio has been expanded with the launch of JACC: Heart Failure.

Defects in original version of Neuron 6F 070 delivery catheter: Penumbra initiates voluntary field removal

Penumbra is initiating a voluntary Field Removal of the original version of Neuron 6F 070 Delivery Catheter. For these catheters, Penumbra has received feedback from some users that the catheter could kink or ovalize in certain anatomical situations.

Columbia University launches CovidWatcher app to track virus spread in NYC

Researchers from Columbia University have launched CovidWatcher, an app that surveys users about their exposure to the new coronavirus, symptoms, access to medical care, and impact on daily life.

CytRx's bafetinib demonstrates significant inhibition of glioblastoma multiforme cell lines in preclinical trial

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced that its drug candidate bafetinib (formerly known as INNO-406) demonstrated statistically significant inhibition of glioblastoma multiforme cell lines in a preclinical trial. Glioblastoma multiforme is the most common and aggressive primary adult brain tumor.

Read more News

› Verified 7 days ago


Emergency Medicine Doctors in Broomall, PA

James J. Flowers, D.O.
Emergency Medicine
Medicare: Medicare Enrolled
Practice Location: 1991 Sproul Rd Ste 600, Broomall, PA 19008
Phone: 484-565-1293    Fax: 610-886-0164
Elizabeth A Bushra, MD
Emergency Medicine
Medicare: Medicare Enrolled
Practice Location: 1991 Sproul Rd Ste 600, Broomall, PA 19008
Phone: 484-565-1293    

Find & Compare Providers Near You: Find and compare doctors, nursing homes, hospitals, and other health care providers in your area that accept Medicare. Get information like: Find a doctor or clinician that accepts Medicare near you.

Doctors and clinicians: Doctors and clinicians include doctors, clinicians and groups who are qualified to practice in many specialties. Each specialty focuses on certain parts of the body, periods of life, conditions, or primary care. The doctors, clinicians, and groups listed here typically work in an office or clinic setting. Also those who currently accept Medicare are included.

Hospitals: Find information about Medicare-certified hospitals and long-term care hospitals in your area, including Veterans Administration medical centers and military hospitals, across the country. Long-term care hospitals serve critically ill and medically complex patients who require extended hospital care.

Data provided: Information on www.medicareusa.org is built using open data sources published by Centers for Medicare & Medicaid Services (CMS) under Freedom of Information Act (FOIA).

© 2024 MedicareUsa. All rights reserved. Maintained by the Agency for Healthcare Research and Quality, U.S. Department of Health and Human Services.